Completed PHASE3 INTERVENTIONAL 2-arm NCT01116778

the Efficacy and Safety of Probiotics eN-Lac® Capsules of Children With Perennial Allergic Rhinitis (PAR)

A Phase III, Double-blind, Randomized, Parallel, Placebo-controlled Study to Evaluate the Efficacy and Safety of Probiotics eN-Lac® Capsules (Lactobacillus Paracasei GMNL-32) for the Treatment of Children With Perennial Allergic Rhinitis

Sponsor: Biomedical Development Corporation

Conditions Lactobacillus Paracasei GMNL-32 (eN-Lac®) Perennial Allergic Rhinitis Probiotics

Interventions Placebo eN-Lac®

Updated 5 times since 2017 Last updated: Aug 31, 2015 Started: May 31, 2010 Primary completion: Jan 31, 2012 Completion: Jun 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Lactobacillus Paracasei GMNL-32 (eN-Lac®) and Perennial Allergic Rhinitis, this trial is completed. The trial is conducted by Biomedical Development Corporation and has accumulated 5 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biomedical Development Corporation
GenMont Biotech Incorporation

Data source: GenMont Biotech Incorporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Taipei, Taiwan
• Xindian, Taiwan